日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML

BRG1/BRM抑制剂联合BET抑制剂或地西他滨治疗高危MECOM重排急性髓系白血病疗效显著。

Fiskus, Warren; Mill, Christopher P; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Birdwell, Christine E; Das, Kaberi; Davis, John A; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Flores, Lauren B; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Wang, Jian; Loghavi, Sanam; Su, Xiaoping; DiNardo, Courtney D; Delwel, Ruud; Bhalla, Kapil N

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

基于BET抑制剂的联合疗法靶向MECOM重排(r) AML中的新型依赖性

Birdwell, Christine E; Fiskus, Warren; Mill, Christopher P; Kadia, Tapan M; Daver, Naval; DiNardo, Courtney D; Sasaki, Koji; Davis, John A; Das, Kaberi; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Flores, Lauren B; Pourebrahim, Rasoul; Yuan, Selina; Su, Xiaoping; Ceribelli, Michele; Bhalla, Kapil N

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML

新型 BCL-xL 降解剂 DT2216 在 JAK2 突变型 MPN 后 AML 临床前模型中的疗效

Wang, Zhe; Skwarska, Anna; Poigaialwar, Gowri; Chaudhry, Sovira; Rodriguez-Meira, Alba; Sui, Pinpin; Olivier, Emmanuel; Jia, Yannan; Gupta, Varun; Fiskus, Warren; Ramage, Cassandra L; Zheng, Guangrong; Schurer, Alexandra; Gritsman, Kira; Papapetrou, Eirini P; Bhalla, Kapil; Zhou, Daohong; Mead, Adam J; Rampal, Raajit K; Tyner, Jeffrey W; Abbas, Hussein A; Pemmaraju, Naveen; Tatarata, Qi Zhang; Konopleva, Marina

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

CDK7抑制剂联合疗法对转化为AML的骨髓增生性肿瘤的临床前疗效

Fiskus Warren, Mill Christopher P, Bose Prithviraj, Masarova Lucia, Pemmaraju Naveen, Dunbar Andrew, Birdwell Christine E, Davis John A, Das Kaberi, Hou Hanxi, Manshouri Taghi, Jain Antrix, Malovannaya Anna, Philip Kevin, Alhamadani Noor, Matthews Alicia, Lin Katie, Flores Lauren B, Loghavi Sanam, DiNardo Courtney, Su Xiaoping, Rampal Raajit K, Bhalla Kapil N

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations

BRG1/BRM与FLT3抑制剂联合治疗对FLT3突变型AML细胞具有优异的临床前疗效

Fiskus, Warren; Mill, Christopher P; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Birdwell, Christine E; Das, Kaberi; Hou, Hanxi; Davis, John A; Jain, Antrix; Malovannaya, Anna; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Reville, Patrick K; Flores, Lauren B; Loghavi, Sanam; Su, Xiaoping; DiNardo, Courtney D; Bhalla, Kapil N

Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

更正:靶向表观遗传共依赖性可增强 Menin 抑制剂在 MLL1 重排或 NPM1 突变型 AML 中的抗 AML 疗效

Fiskus, Warren; Mill, Christopher P; Birdwell, Christine; Davis, John A; Das, Kaberi; Boettcher, Steffen; Kadia, Tapan M; DiNardo, Courtney D; Takahashi, Koichi; Loghavi, Sanam; Soth, Michael J; Heffernan, Tim; McGeehan, Gerard M; Ruan, Xinjia; Su, Xiaoping; Vakoc, Christopher R; Daver, Naval; Bhalla, Kapil N

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

tasquinimod联合疗法治疗晚期骨髓增生性肿瘤急变期患者的临床前疗效

Fiskus, Warren; Masarova, Lucia; Mill, Christopher P; Birdwell, Christine E; Das, Kaberi; Hou, Hanxi; Davis, John A; Jain, Antrix; Malovannaya, Anna; Manshouri, Taghi; Dunbar, Andrew; Sharma, Surbhi; Kadia, Tapan M; DiNardo, Courtney D; Bose, Prithviraj; Pemmaraju, Naveen; Loghavi, Sanam; Su, Xiaoping; Rampal, Raajit K; Törngren, Marie; Bhalla, Kapil N

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

奥马西他滨和维奈托克用于治疗复发/难治性急性髓系白血病或伴有突变 RUNX1 的骨髓增生异常综合征

DiNardo, Courtney D; Jen, Wei-Ying; Montalban-Bravo, Guillermo; Wang, Xuemei; Loghavi, Sanam; Lavu, Sravanthi; Short, Nicholas J; Chien, Kelly; Issa, Ghayas C; Pemmaraju, Naveen; Yilmaz, Musa; Andreeff, Michael; Borthakur, Gautam; Kadia, Tapan M; Daver, Naval G; Garcia-Manero, Guillermo; Mill, Christopher P; Su, Xiaoping; Fiskus, Warren; Bhalla, Kapil N

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

BRG1/BRM抑制剂靶向AML干细胞,与BET或menin抑制剂联合使用时,在临床前疗效显著优于其他抑制剂。

Fiskus, Warren; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Mill, Christopher P; Birdwell, Christine E; Das, Kaberi; Davis, John A; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Reville, Patrick K; Wang, Jian; Loghavi, Sanam; Sen, Rwik; Ruan, Xinjia; Su, Xiaoping; Flores, Lauren B; DiNardo, Courtney D; Bhalla, Kapil N

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

靶向表观遗传机制治疗伴有3q26病变和EVI1过表达的急性髓系白血病的临床前疗效

Birdwell, Christine E; Fiskus, Warren; Kadia, Tapan M; Mill, Christopher P; Sasaki, Koji; Daver, Naval; DiNardo, Courtney D; Pemmaraju, Naveen; Borthakur, Gautam; Davis, John A; Das, Kaberi; Sharma, Sunil; Horrigan, Stephen; Ruan, Xinjia; Su, Xiaoping; Khoury, Joseph D; Kantarjian, Hagop; Bhalla, Kapil N